shr-2004
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jan 31, 2024 (NCT06220123)
Timeline
Indications
Mechanism of action
- Coagulation factor XIINHIBITOR
F11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06825416 | Phase 3 | Mar 14, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06220123 | Phase 2 | Jan 31, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1